AAAAAA

   
Results: 1-10 |
Results: 10
IS THERE A PHARMACOKINETIC INTERACTION BETWEEN FOSCARNET AND ZALCITABINE DURING CONCOMITANT ADMINISTRATION
Authors: AWEEKA FT BRODY SR JACOBSON M BOTWIN K MARTINMUNLEY S
Citation: Ft. Aweeka et al., IS THERE A PHARMACOKINETIC INTERACTION BETWEEN FOSCARNET AND ZALCITABINE DURING CONCOMITANT ADMINISTRATION, Clinical therapeutics, 20(2), 1998, pp. 232-243
PHARMACOKINETICS AND ABSOLUTE BIOAVAILABILITY OF ORAL FOSCARNET IN HUMAN IMMUNODEFICIENCY VIRUS-SEROPOSITIVE PATIENTS
Authors: NOORMOHAMED FH YOULE MS HIGGS CJ MARTINMUNLEY S GAZZARD BG LANT AF
Citation: Fh. Noormohamed et al., PHARMACOKINETICS AND ABSOLUTE BIOAVAILABILITY OF ORAL FOSCARNET IN HUMAN IMMUNODEFICIENCY VIRUS-SEROPOSITIVE PATIENTS, Antimicrobial agents and chemotherapy, 42(2), 1998, pp. 293-297
EFFECT OF FOSCARNET CREAM ON EXPERIMENTAL UV RADIATION-INDUCED HERPESLABIALIS
Authors: BERNSTEIN DI SCHLEUPNER CJ EVANS TG BLUMBERG DA BRYSON Y GRAFFORD K BROBERG P MARTINMUNLEY S SPRUANCE SL
Citation: Di. Bernstein et al., EFFECT OF FOSCARNET CREAM ON EXPERIMENTAL UV RADIATION-INDUCED HERPESLABIALIS, Antimicrobial agents and chemotherapy, 41(9), 1997, pp. 1961-1964
TREATMENT OF GASTROINTESTINAL CYTOMEGALOVIRUS-INFECTION WITH TWICE-DAILY FOSCARNET - A PILOT-STUDY OF SAFETY, EFFICACY, AND PHARMACOKINETICS IN PATIENTS WITH AIDS
Authors: DIETERICH DT POLES MA LEW EA MARTINMUNLEY S JOHNSON J NIX D FAUST MJ
Citation: Dt. Dieterich et al., TREATMENT OF GASTROINTESTINAL CYTOMEGALOVIRUS-INFECTION WITH TWICE-DAILY FOSCARNET - A PILOT-STUDY OF SAFETY, EFFICACY, AND PHARMACOKINETICS IN PATIENTS WITH AIDS, Antimicrobial agents and chemotherapy, 41(6), 1997, pp. 1226-1230
RELATIONSHIP BETWEEN FOSCARNET EXPOSURE, BASE-LINE CYTOMEGALOVIRUS (CMV) BLOOD CULTURE AND THE TIME TO PROGRESSION OF CMV RETINITIS IN HIV-POSITIVE PATIENTS
Authors: DRUSANO GL AWEEKA F GAMBERTOGLIO J JACOBSON M POLIS M LANE HC EATON C MARTINMUNLEY S
Citation: Gl. Drusano et al., RELATIONSHIP BETWEEN FOSCARNET EXPOSURE, BASE-LINE CYTOMEGALOVIRUS (CMV) BLOOD CULTURE AND THE TIME TO PROGRESSION OF CMV RETINITIS IN HIV-POSITIVE PATIENTS, AIDS, 10(10), 1996, pp. 1113-1119
PHARMACOKINETICS (PK) OF CONCOMITANTLY ADMINISTERED FOSCARNET AND DIDEOXYCYTIDINE
Authors: BOTWIN KJ MARTINMUNLEY S AWEEKA F
Citation: Kj. Botwin et al., PHARMACOKINETICS (PK) OF CONCOMITANTLY ADMINISTERED FOSCARNET AND DIDEOXYCYTIDINE, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 50-50
FOSCARNET PHARMACOKINETICS (PK) DURING CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS (CAPD)
Authors: FLOREN L GAMBERTOGLIO JG MARTINMUNLEY S AWEEKA F
Citation: L. Floren et al., FOSCARNET PHARMACOKINETICS (PK) DURING CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS (CAPD), Clinical pharmacology and therapeutics, 59(2), 1996, pp. 52-52
PHARMACOKINETICS (PK) OF CONCOMITANT FOSCARNET AND DIDANOSINE IN PATIENTS (PTS) WITH HIV DISEASE
Authors: AWEEKA FT MATHUR V DORSEY R JACOBSON MA MARTINMUNLEY S PIRRUNG D FRANCO J LIZAK P JOHNSON J GAMBERTOGLIO J
Citation: Ft. Aweeka et al., PHARMACOKINETICS (PK) OF CONCOMITANT FOSCARNET AND DIDANOSINE IN PATIENTS (PTS) WITH HIV DISEASE, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 143-143
PHASE-II DOSE-RANGING TRIAL OF FOSCARNET SALVAGE THERAPY FOR CYTOMEGALOVIRUS RETINITIS IN AIDS PATIENTS INTOLERANT OF OR RESISTANT TO GANCICLOVIR (ACTG PROTOCOL 093)
Authors: JACOBSON MA WULFSOHN M FEINBERG JE DAVIS R POWER M OWENS S CAUSEY D HEATHCHIOZZI ME MURPHY RL CHEUNG TW DIETERICH DT SPECTOR SA MCKINLEY GF PARENTI DM CRUMPACKER C NISHIMOTO B LEEDOM JM KRAMER F COHEN C LOFTUS J KESSLER HA POTTAGE JC BENSON CA PHAIR JP GERITS P CHUSID E SACKS HS FRIEDBERG D CURRANKRIKORIAN K VALENTINE FT MENG TC FREEMAN WR MEIXNER L RICHMAN D ODONNELL JJ KIMBRELL C BOGGIO K LARSON J WHITMORE PV SIMON GL LELACHEUR S FIFE K ZWICKL B RELUE J STEIGBIGEL RT FUHRER J DONLON W BURK RA PORTMORE AC WEISSBACH NE HOOTON TM HOLZWORTH P DAVISON S COLLIER AC POWDERLY WG KLEBERT M ROYAL M SEYFRIED W SQUIRES KC WEISS W BARBACCI M BECKER RL JABS D BARTLETT JG PARA MF JONES M NEIDIG JL FASS RJ VANDERHORST C KYLSTRA J RAASCH R BLOODGOOD K WOLITZ R KIRK S ROLFE L PATRONEREESE J BARTLETT JA WASKIN HA WILLIAMS DK SHIP KW KAHL P ASSAYKEEN T KAROL C MARTINMUNLEY S SUMNER P
Citation: Ma. Jacobson et al., PHASE-II DOSE-RANGING TRIAL OF FOSCARNET SALVAGE THERAPY FOR CYTOMEGALOVIRUS RETINITIS IN AIDS PATIENTS INTOLERANT OF OR RESISTANT TO GANCICLOVIR (ACTG PROTOCOL 093), AIDS, 8(4), 1994, pp. 451-459
PHARMACOKINETICS (PK) OF FOSCARNET (F) IN PATIENTS WITH VARYING DEGREES OF RENAL-FUNCTION AND HEMODIALYSIS (HD)
Authors: AWEEKA FT PIRRUNG D LIZAK P MATHUR V OMACHI R JACOBSON MA SCHOENFELD P TSUNODA S COGAN M MARTINMUNLEY S GAMBERTOGLIO JG
Citation: Ft. Aweeka et al., PHARMACOKINETICS (PK) OF FOSCARNET (F) IN PATIENTS WITH VARYING DEGREES OF RENAL-FUNCTION AND HEMODIALYSIS (HD), Clinical pharmacology and therapeutics, 55(2), 1994, pp. 195-195
Risultati: 1-10 |